A method to compare prospective and historical cohorts to evaluate drug effects. Application to the analysis of early treatment effectiveness of intramuscular interferon-β1a in multiple sclerosis patients
Giulia Mallucci, Roberto Bergamaschi(Fondazione Istituto Neurologico Nazionale Casimiro Mondino), Elisa Puma(Biogen (Italy)), Valentina Zipoli(University of Florence), María Trojano(University of Bari Aldo Moro), Massimiliano Mirabella(Università Cattolica del Sacro Cuore), Maria Pia Amato(University of Florence), Maria Buccafusca(University of Siena), Elisabetta Ferraro(IRCCS Ospedale San Raffaele), Francesco Patti(University of Catania), Katrin Plewnia, Vincenzo Brescia Morra(Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari), Mauro Zaffaroni(Associazione Italiana Sclerosi Multipla), Gianluca Moscato, Lucia Moiola(Vita-Salute San Raffaele University)
Cited by 1
Related Papers
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Multiple Sclerosis Severity Score
|Neurology|2005|959
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
|Multiple Sclerosis Journal|2018|706
Multiple sclerosis progression: time for a new mechanism-driven framework
|The Lancet Neurology|2022|624